Dive Brief: AbbVie announced Friday a new agreement with its longtime partner Gedeon Richter to research and develop dopamine-regulating treatments for neuropsychiatric diseases. According …
Dive Brief: The top-selling product for French pharmaceutical giant Sanofi now has two more competitors in the U.S. market, as the Food and Drug Administration …
While a smaller biotech company, Biohaven has succeeded in a market led by large pharmaceutical firms like Lilly, AbbVie and, in the preventive treatment setting, …
For years, AbbVie’s business has relied on Humira. One of the world’s top-selling medicines, Humira brought in close to $20 billion for AbbVie in each …
Biohaven has built itself into a nearly $10 billion company on the strength of its migraine drug Nurtec, which surprised Wall Street with second-quarter sales …
The promise of biosimilars — that competition would bring down the prices of complex biological drugs — hasn’t materialized in the U.S. in the way …
The market is expected to register a CAGR of 8.5% during the forecast period 2018 to 2023. North America dominates the market due to the …
